NovaBridge Biosciences (NBP) Operating Leases (2019 - 2025)

NovaBridge Biosciences (NBP) has reported Operating Leases for 7 consecutive years, with $2.2 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Leases fell 29.03% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 29.03% YoY) and the FY2025 annual result came in at $2.2 million, down 29.03% from the prior year.
• Operating Leases declined to $2.2 million in Q4 2025 per NBP's latest filing, from $2.4 million in the prior quarter.
• Over the last five years, Operating Leases for NBP reached as high as $12.8 billion in Q4 2021 and fell as low as $2.2 million in Q4 2025.
• A 5-year average of $987.6 million and a median of $3.1 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases surged 1529598.65% — and 2022, when it slumped 99.96%.
• Year by year, Operating Leases stood at $12.8 billion in 2021, then sank by 99.96% to $4.5 million in 2022, then jumped by 38.58% to $6.2 million in 2023, then tumbled by 50.93% to $3.1 million in 2024, then slipped by 29.03% to $2.2 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $2.2 million, $2.4 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.